



### Auryxia™ (ferric citrate) – Drug Shortage

- The **drug shortage** of Keryx Biopharmaceuticals' **Auryxia (ferric citrate)** tablets is ongoing. Auryxia has been unavailable for at least 90 days due to a production-related issue.
  - The issue involves the conversion of the active ingredient to the finished drug product at its contract manufacturer. This has led to variable production yields of the finished drug product and Keryx has exhausted its reserve.
  - The current stock of Auryxia is not sufficient to provide uninterrupted patient access to Auryxia thus Keryx is working with its manufacturers to resolve this issue and restore adequate supply.
  - Estimated availability of Auryxia is during the 4<sup>th</sup> quarter of 2016.
- Auryxia is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

Product Description	Strength	NDC #
Auryxia (ferric citrate)	210 mg tablets	59922-0631-01

### Action Plan

- Information about the long-term drug shortage of Auryxia tablets will be communicated with clients. Formulary changes may be made, as appropriate.
- Information regarding Auryxia will be posted on the [optumrx.com](http://optumrx.com) portals.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.